Legal & General Group
ACTU

Legal & General Group’s Actuate Therapeutics ACTU Stock Holding History

Legal & General Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,107
Closed -$3.03K – 3559
2026
Q1 		$3.03K Sell
1,107
-172
-13% -$713 ﹤0.01% 3326
2025
Q4 		$7.83K Buy
1,279
+571
+81% +$3.92K ﹤0.01% 3295
2025
Q3 		$4.74K Hold
708
– – ﹤0.01% 3368
2025
Q2 		$4.33K Buy
+708
New +$6.19K ﹤0.01% 3393

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Legal & General Group's ACTU Position: Q2 2026 in Review

Legal & General Group sold out of Actuate Therapeutics (ACTU) in Q2 2026, closing a stake of 1,107 shares — an estimated $3.03K sold.

Legal & General Group first reported a position in ACTU in Q2 2025 and held it in 4 quarters. The position peaked at $7.83K in Q4 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Legal & General Group reported no remaining Actuate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Legal & General Group sold 1,107 Actuate Therapeutics shares in Q2 2026, an estimated $3.03K.
  • Legal & General Group first reported a position in Actuate Therapeutics in Q2 2025 and held it in 4 quarters.
  • Legal & General Group's Actuate Therapeutics position peaked at $7.83K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.